Frequency of different clinical presentations/ symptoms of irritable bowel syndrome in patients presenting to the outpatient department of lady reading hospital Peshawar
Keywords:
clinical presentations, frequent stools, looser stools, infrequent stools, harder stools, abdominal painAbstract
In the absence of any structural aetiology, irritable bowel syndrome is a condition of gastrointestinal motility and sensation that is defined by persistent abdominal pain and irregular bowel movements. It is the communal reasons for gastroenterology consultations. Therefore, knowledge of the relative frequency of these symptoms in our population will enable healthcare practitioners to tailor their management to the symptom patterns of our population. Objective: To determine the frequency of different clinical presentations/symptoms (frequent stools, looser stools, infrequent stools, harder stools, abdominal pain) of irritable bowel syndrome in patients presenting to the outpatient department of Lady Reading Hospital, Peshawar. Place and Duration: In Gastroenterology outpatient department of Lady Reading Hospital, Peshawar for six months duration from 25th June, 2019 to 25th December, 2019. Study Design: A Cross-sectional Study. Methods: In this study a total 192 patients were observed. The patients were given a questionnaire containing questions about their clinical presentation including present and past symptoms. These questions were including details of how frequently they need to pass stools, consistency/form of stools (graded according to Bristol Stool Chart) as well as presence or absence of pain.
Downloads
References
American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 suppl):S1–5.
Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment PharmacolTher. 2009;20(Suppl 2):1–9.
Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease?. Gastroenterol Clin North Am. Jun 2005;34(2):235-45.
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-58.
Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651-60.
Ghoshal UC, Abraham P, Bhatt C. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008;27:22-8.
Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Frequency ofirritable bowel syndrome in college students.J Ayub Med Coll. 2005;17(4):9–11.
Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Irritable bowel syndrome and health seeking behavior in different communities of Pakistan. J Pak Med Assoc.2007;57(6):285–7.
Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. ClinExpGastroenterol. 2011;4:43–8.
Krogius-Kurikka L, Lyra A, Malinen E. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.
Majewski M, Reddymasu S, Sostarich S, Foran P, McCallum R. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. AmJ Med Sci.2007;333:266–70.
Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2(6138):653-4
Olden KW. Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. Cleve Clin J Med. 2003;70(suppl 2):S3–7.
Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Sub analysis of a double-blind randomized controlled study. Dig Dis Sci. 2010; 51(8):1297–301.
Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2010;95(12):3503–6.
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2008;98(2):412–9.
Pimentel M., Lembo A., Chey W., Zakko S., Ringel Y., Yu J., et al. TARGET Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation. NEngl J Med. 2011;364:22–32.
Schoepfer A. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment PharmacolTher.2012;36(11):1084–93.
Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15
Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. Apr 2010;105(4):848-58.
Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. NeurogastroenterolMotil. 2010;22(5):512–9.
Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:43–7.
Wong RK, Drossman DA, Weinland SR, Morris CB, Leserman J, Hu Y, et al. Partner burden in irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 2013;11(2):151-5..
Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169–74.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.